论文部分内容阅读
目的 :研究参麦注射液对晚期原发性肝癌 (以下简称肝癌 )患者细胞免疫功能的影响。方法 :检测 2 9例肝癌患者应用参麦注射液治疗前后血清可溶性白细胞介素 - 2受体 (SIL- 2 R)及 T淋巴细胞亚群水平。结果 :治疗前 SIL- 2 R及 CD8明显高于正常对照组 ,CD4水平显著低于正常对照组 ,治疗后血清 SIL- 2 R及 CD8较治疗前显著降低 ,CD4水平明显升高 ,且治疗后 CD4,CD8,SIL - 2 R水平与正常对照组比较无明显差异。结论 :参麦注射液对肝癌患者免疫功能有广泛调节作用
Objective: To study the effect of Shenmai injection on cellular immune function in patients with advanced primary liver cancer (hereinafter referred to as liver cancer). Methods: Serum levels of soluble interleukin - 2 receptor (SIL-2R) and T lymphocyte subsets were detected in 29 hepatocellular carcinoma patients before and after treatment with Shenmai injection. Results: The levels of SIL-2 R and CD8 before treatment were significantly higher than those of the normal control group, and the CD4 levels were significantly lower than that of the normal control group. After treatment, the levels of SIL-2 R and CD8 were significantly decreased and the CD4 level was significantly increased CD4, CD8, SIL - 2 R levels compared with the normal control group no significant difference. Conclusion: Shenmai injection has broad regulating effect on the immune function of patients with liver cancer